2029 and Drug Development - Pharmacist Digest

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Pharmaceutical Technology

JULY 1, 2025

Further, they say the balance attempted between encouraging innovation and improving access instead could be contradictory for drug developers and investors, in a way that is emblematic of a fragmented EU. Industry reactions have been mixed.

Packaging

Packaging Drug Development Chemotherapy Biosimilars

Organon drug for endometriosis falls short in mid-stage study

BioPharma Dive

JULY 2, 2025

Chief Executive Kevin Ali called the drug a “multibillion dollar opportunity” during the J.P. The company had hoped to kick off Phase 3 research in 2026 and launch the medicine around 2029. Organon acquired the drug in its purchase of Forendo Pharma in 2021. Morgan Healthcare Conference in January.

Drug Pricing

Drug Pricing Drug Development Vaccines

Vor Bio back from brink with autoimmune drug deal rising to $4bn

Pharmaceutical Technology

JUNE 26, 2025

A month and a half after winding operations and laying off almost all its staff, Vor Bio has emerged from the brink with a licensing deal potentially rising to $4bn for an autoimmune drug developed by Chinese biotech RemeGen. GlobalData is the parent company of Pharmaceutical Technology.

Packaging

Packaging Communication Hospitals Drug Development

WHO endorses Gilead’s Yeztugo for HIV prevention

Pharmaceutical Technology

JULY 14, 2025

A report by UNAIDS predicts that six million new HIV infections and four million AIDS-related deaths could occur between 2025 and 2029 if US-supported HIV treatment and prevention services collapse.

Vaccines

Vaccines Packaging Hospitals Communication

The Sun Has Started to Set on the Rare Pediatric Disease Priority Review Voucher Program – But It Can Still be Saved

FDA Law Blog: Biosimilars

DECEMBER 23, 2024

Earlier in the week, it was reported that there was a bipartisan agreement on a bill that would have funded the government and extended the first sunset date for the rare pediatric disease priority review voucher program for nearly 5 years, until September 30, 2029.

Drug Development

EHDS regulation will depend on strong patient confidence

Pharmaceutical Technology

JUNE 25, 2025

The regulation came into force in March 2025; however, it has not yet come into application, with this set to happen in March 2029. Experts also emphasised that the secondary data will help with accelerating drug development cycles, making clinical trials more cost-efficient, and improving real-world insights.

Communication

Communication Hospitals Packaging Pharmaceutical Companies

A Temporary Extension for the Rare Pediatric Disease Priority Review Voucher with a Longer-Term Extension in Sight?

FDA Law Blog: Biosimilars

OCTOBER 13, 2024

It is extremely difficult, if not impossible, to do the long-term planning and substantial fundraising required for drug development without knowing whether such an important and valuable incentive will be there. We heard and felt the anxiety from many of our clients about the uncertainty this caused.

Documentation

Documentation Drug Development

Psychedelic drug market to reach $7.2 bn in 2029: GlobalData

Express Pharma

SEPTEMBER 24, 2023

The psychedelic drug market is on the brink of extraordinary growth, projected to soar to $7.2 billion by 2029, reflecting a robust 55 per cent compound annual growth rate (CAGR). This ascent is propelled by favorable regulatory developments, including pioneering clinical trial guidelines from the FDA. billion in sales in 2029.

Drug Development

Drug Development Compounding

Single-use technology propelling upstream bioprocessing market expansion

European Pharmaceutical Review

FEBRUARY 20, 2024

million by 2029. percent between 2022 and 2029. Other key influences helping the upstream bioprocessing market expand include drug development, antibody manufacturing, as well as a higher need for cell therapy research. Additionally, the research calculated that market is anticipated to undergo a CAGR of 6.85

Process Improvement

Process Improvement Biosimilars Drug Development

Cell and gene therapy will be top industry trend for pharma in 2024: GlobalData

Express Pharma

DECEMBER 28, 2023

One of the recent examples is Bayer’s announcement of a cooperation with Shanghai Pharmaceuticals China in November 2023 to set up its first Chinese lab for CGT and cancer drug development. According to GlobalData estimates, the global CGT market is projected to reach $80 billion by 2029.

Drug Development

The future of pain medication: are cannabinoids the solution to the opioid epidemic?

Pharmaceutical Technology

JUNE 12, 2023

In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. However, 2017 saw the discontinuation of nabiximols from Phase III development in the US for cancer pain, due to lack of efficacy.

Immunity

Immunity Immunization Drug Development

First-in-class DLL3-targeting BiTE could be the next big player in SCLC treatment: GlobalData

Express Pharma

NOVEMBER 13, 2023

However, tarlatamab, a bispecific T-cell engager (BiTE) developed by Amgen, recently demonstrated potentially registrational data at the European Society for Medical Oncology (ESMO) 2023 Congress from the Phase II DeLLphi-301 trial. The Phase II DeLLphi-301 trial focused on patients with SCLC undergoing two prior treatment regimens.

Drug Development

Legislative Update: Congress Extends Funding for Patient Programs

Putting Patients First Blog

SEPTEMBER 30, 2024

The goal of the rare pediatric disease PRV program is to incentivize drug development for rare pediatric diseases. 3433 the Give Kids a Chance Act, which reauthorized the voucher program through 2029. Earlier this month, the House Energy and Commerce Committee unanimously passed H.R.

Department of Veterans Affairs

Department of Veterans Affairs Packaging Drug Development

Antibody-drug conjugates: paving the future of oncology clinical development

European Pharmaceutical Review

OCTOBER 26, 2023

Antibody-drug conjugates (ADCs), such as datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan, have demonstrated compelling evidence of efficacy in oncology across numerous diseases in recent months.

Chemotherapy

Chemotherapy Drug Development

Sustainability and technology advancement driving spectroscopy market

European Pharmaceutical Review

JANUARY 21, 2025

billion in 2029 at a compound annual growth rate (CAGR) of 7.9 Technological advancement in the process spectroscopy market As a key part of drug development and drug formulation, the report highlighted that demand for process spectroscopy is being fuelling by the growing pharmaceutical industry. It will grow to $31.77

Compounding

Compounding Drug Development

Pharmacist Digest

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Organon drug for endometriosis falls short in mid-stage study

Trending Sources

Vor Bio back from brink with autoimmune drug deal rising to $4bn

WHO endorses Gilead’s Yeztugo for HIV prevention

The Sun Has Started to Set on the Rare Pediatric Disease Priority Review Voucher Program – But It Can Still be Saved

EHDS regulation will depend on strong patient confidence

A Temporary Extension for the Rare Pediatric Disease Priority Review Voucher with a Longer-Term Extension in Sight?

Psychedelic drug market to reach $7.2 bn in 2029: GlobalData

Single-use technology propelling upstream bioprocessing market expansion

Cell and gene therapy will be top industry trend for pharma in 2024: GlobalData

The future of pain medication: are cannabinoids the solution to the opioid epidemic?

First-in-class DLL3-targeting BiTE could be the next big player in SCLC treatment: GlobalData

Legislative Update: Congress Extends Funding for Patient Programs

Antibody-drug conjugates: paving the future of oncology clinical development

Sustainability and technology advancement driving spectroscopy market

Stay Connected